Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15112163 | 1.00 | CDK5 (0.31) | CDK5CDK5R1KMT2A | |
| SCHEMBL15112165 | 1.00 | CDK5 (0.31) | CDK5CDK5R1KMT2A | |
| Hydrochloric Acid SCHEMBL10325311 | 0.98 | KMT2A (0.33) | CDK5CDK5R1KMT2A | |
| Hydrochloric Acid SCHEMBL15112167 | 0.98 | KMT2A (0.33) | CDK5CDK5R1KMT2A | |
| Hydrochloric Acid SCHEMBL15411559 | 0.98 | KMT2A (0.33) | CDK5CDK5R1KMT2A | |
| Hydrochloric Acid SCHEMBL15411561 | 0.98 | KMT2A (0.33) | CDK5CDK5R1KMT2A | |
| Formic Acid SCHEMBL15412948 | 0.88 | — | — | |
| SCHEMBL2066341 | 0.79 | — | — | |
| SCHEMBL10261160 | 0.78 | CDK5 (0.32) | CDK5CDK5R1KMT2A | |
| SCHEMBL6848622 | 0.78 | CDK5 (0.32) | CDK5CDK5R1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| US-20160243059-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE BRAIN DISEASE COMPRISING MULTI-TARGETING COMPOUNDS | UNIST ACADEMY-INDUSTRY RESEARCH CORPORATION (KR) | 2016-08-25 | — | — | US | claimed |
| EP-2454262-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | Abbott Laboratories (US) | 2012-05-23 | — | — | EP | claimed |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | claimed |
| WO-2011008830-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | WO | claimed |
| US-4851565-A | FROM DI- OR POLYAMINES, UREA AND MONOFUNCTIONAL ALCOHOL | BASF AKTIENGESELLSCHAFT (DE) | 1989-07-25 | — | — | US | claimed |
| US-4497963-A | ETHYLENICALLY UNSATURADED POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 1985-02-05 | — | — | US | claimed |
| EP-0018588-B1 | PROCESS FOR PREPARING ALIPHATIC AND CYCLOALIPHATIC DI- AND POLYURETHANES | BASF Aktiengesellschaft (DE) | 1982-12-29 | — | — | EP | claimed |
| EP-0018586-B1 | PROCESS FOR PREPARING ALIPHATIC AND CYCLOALIPHATIC DI- AND POLYURETHANES | BASF Aktiengesellschaft (DE) | 1982-12-08 | — | — | EP | claimed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-4497963-A | ETHYLENICALLY UNSATURADED POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 1985-02-05 | — | — | US | disclosed |
| EP-0113252-A2 | Process for producing block copolyamide | TORAY INDUSTRIES, INC. (JP) | 1984-07-11 | — | — | EP | disclosed |
| EP-0018588-B1 | PROCESS FOR PREPARING ALIPHATIC AND CYCLOALIPHATIC DI- AND POLYURETHANES | BASF Aktiengesellschaft (DE) | 1982-12-29 | — | — | EP | disclosed |
| EP-0018586-B1 | PROCESS FOR PREPARING ALIPHATIC AND CYCLOALIPHATIC DI- AND POLYURETHANES | BASF Aktiengesellschaft (DE) | 1982-12-08 | — | — | EP | disclosed |
| EP-0018588-A1 | Process for preparing aliphatic and cycloaliphatic di- and polyurethanes | BASF Aktiengesellschaft (DE) | 1980-11-12 | — | — | EP | disclosed |
| EP-0018586-A1 | Process for preparing aliphatic and cycloaliphatic di- and polyurethanes | BASF Aktiengesellschaft (DE) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CDK5 133/4885CDK5R1 195/4885KMT2A 2966/4885 |
| US-20110015172-A1 | PYRROLOPYRAZINE INHIBITORS OF KINASES | CDC7, CDK7, CDK17 | CDK5 57/4885CDK5R1 92/4885KMT2A 1288/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | CDK5 125/4885CDK5R1 190/4885KMT2A 2916/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | CDK5 438/4885CDK5R1 709/4885KMT2A 3880/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | CDK5 584/4885CDK5R1 1320/4885KMT2A 601/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | CDK5 819/4885CDK5R1 428/4885KMT2A 3878/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CDK5 395/4885CDK5R1 1358/4885KMT2A 1704/4885 |
| US-20160243059-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DEGENERATIVE BRAIN DISEASE COMPRISING MULTI-TARGETING COMPOUNDS | APP, PSEN1, BACE1 | CDK5 1303/4885CDK5R1 1985/4885KMT2A 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.